Caedo Oncology develops novel monoclonal antibodies for cancer immunotherapy, focusing on inducing programmed cell death in cancer cells through unique pathways
Caedo Oncology develops novel monoclonal antibodies for cancer immunotherapy, focusing on inducing programmed cell death in cancer cells through unique pathways.